DK4073098T5 - Ultralangtidsvirkende insulin-Fc-fusionsproteiner og fremgangsmåder til anvendelse - Google Patents

Ultralangtidsvirkende insulin-Fc-fusionsproteiner og fremgangsmåder til anvendelse Download PDF

Info

Publication number
DK4073098T5
DK4073098T5 DK20830444.4T DK20830444T DK4073098T5 DK 4073098 T5 DK4073098 T5 DK 4073098T5 DK 20830444 T DK20830444 T DK 20830444T DK 4073098 T5 DK4073098 T5 DK 4073098T5
Authority
DK
Denmark
Prior art keywords
ultra
methods
long
fusion proteins
acting insulin
Prior art date
Application number
DK20830444.4T
Other languages
English (en)
Other versions
DK4073098T3 (da
Inventor
Thomas M Lancaster
Todd C Zion
Original Assignee
Akston Biosciences Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akston Biosciences Corp filed Critical Akston Biosciences Corp
Publication of DK4073098T3 publication Critical patent/DK4073098T3/da
Application granted granted Critical
Publication of DK4073098T5 publication Critical patent/DK4073098T5/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0684Cells of the urinary tract or kidneys
    • C12N5/0686Kidney cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/62Insulins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0681Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
DK20830444.4T 2019-12-19 2020-12-07 Ultralangtidsvirkende insulin-Fc-fusionsproteiner og fremgangsmåder til anvendelse DK4073098T5 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962950803P 2019-12-19 2019-12-19
US202062988441P 2020-03-12 2020-03-12
PCT/US2020/063673 WO2021126584A1 (en) 2019-12-19 2020-12-07 Ultra-long acting insulin-fc fusion proteins and methods of use

Publications (2)

Publication Number Publication Date
DK4073098T3 DK4073098T3 (da) 2023-11-20
DK4073098T5 true DK4073098T5 (da) 2024-07-22

Family

ID=74104207

Family Applications (1)

Application Number Title Priority Date Filing Date
DK20830444.4T DK4073098T5 (da) 2019-12-19 2020-12-07 Ultralangtidsvirkende insulin-Fc-fusionsproteiner og fremgangsmåder til anvendelse

Country Status (17)

Country Link
US (3) US11352407B2 (da)
EP (2) EP4282473A3 (da)
JP (1) JP7405486B2 (da)
KR (2) KR102865175B1 (da)
CN (1) CN114846025B (da)
AU (1) AU2020407365B2 (da)
BR (1) BR112022012071A2 (da)
CA (1) CA3159486A1 (da)
DK (1) DK4073098T5 (da)
FI (1) FI4073098T3 (da)
HR (1) HRP20231433T1 (da)
HU (1) HUE064376T2 (da)
IL (1) IL294051A (da)
LT (1) LT4073098T (da)
SI (1) SI4073098T1 (da)
WO (1) WO2021126584A1 (da)
ZA (1) ZA202206047B (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210029210A (ko) 2018-06-29 2021-03-15 악스톤 바이오사이언시스 코퍼레이션 초장기 작용 인슐린-fc 융합 단백질 및 사용 방법
FI4073098T3 (fi) 2019-12-19 2023-11-15 Akston Biosciences Corp Ultrapitkävaikutteiset insuliini-Fc-fuusioproteiinit ja niiden käyttömenetelmät
US11186623B2 (en) 2019-12-24 2021-11-30 Akston Bioscience Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
US11192930B2 (en) 2020-04-10 2021-12-07 Askton Bioscences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
CN116096733A (zh) 2020-04-10 2023-05-09 阿卡斯通生物科学公司 Covid-19融合蛋白的抗原特异性免疫疗法和使用方法
US11198719B2 (en) 2020-04-29 2021-12-14 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
US11667689B2 (en) 2021-07-23 2023-06-06 Akston Biosciences Corporation Insulin-Fc fusion proteins and methods of use to treat cancer
TWI871539B (zh) 2021-11-15 2025-02-01 美商美國禮來大藥廠 可保存之調配物

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030040601A1 (en) 2001-06-08 2003-02-27 Ivan Diers Method for making insulin precursors and insulin analog precursors
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US8569231B2 (en) 2009-03-20 2013-10-29 Smartcells, Inc. Soluble non-depot insulin conjugates and uses thereof
CA2754408A1 (en) 2009-03-30 2010-10-14 Boehringer Ingelheim International Gmbh Fusion proteins comprising canine fc portions
CN101891823B (zh) 2010-06-11 2012-10-03 北京东方百泰生物科技有限公司 一种Exendin-4及其类似物融合蛋白
WO2012015692A2 (en) 2010-07-28 2012-02-02 Smartcells, Inc. Recombinantly expressed insulin polypeptides and uses thereof
AU2011282977A1 (en) 2010-07-28 2013-02-21 Smartcells, Inc. Drug-ligand conjugates, synthesis thereof, and intermediates thereto
AR087433A1 (es) 2011-08-08 2014-03-26 Merck Sharp & Dohme Analogos de insulina n-glicosilados
EP2780463A4 (en) 2011-11-18 2015-07-01 Merck Sharp & Dohme FC-CONTAINING POLYPEPTIDES WITH INCREASED INFLAMMATORY FEATURES AND INCREASED FCRN BINDING
KR102041412B1 (ko) 2011-12-30 2019-11-11 한미사이언스 주식회사 면역글로불린 Fc 단편 유도체
DK2804623T3 (da) 2012-01-12 2019-11-11 Bioverativ Therapeutics Inc Kimære faktor viii-polypeptider og anvendelser deraf
CN103509118B (zh) 2012-06-15 2016-03-23 郭怀祖 胰岛素-Fc融合蛋白
TWI708782B (zh) 2013-02-26 2020-11-01 南韓商韓美藥品股份有限公司 新穎胰島素類似物及其用途
WO2014190040A1 (en) * 2013-05-21 2014-11-27 President And Fellows Of Harvard College Engineered heme-binding compositions and uses thereof
EP3194429A4 (en) 2014-09-18 2018-06-13 Askgene Pharma, Inc. Novel feline erythropoietin receptor agonists
WO2016105545A2 (en) 2014-12-24 2016-06-30 Case Western Reserve University Insulin analogues with enhanced stabilized and reduced mitogenicity
JP2018504911A (ja) 2015-01-29 2018-02-22 ネックスヴェット オーストラリア プロプライエタリー リミテッド 治療及び診断剤
US10894089B2 (en) 2015-02-17 2021-01-19 Hanmi Pharm. Co., Ltd. Long-acting insulin or insulin analogue conjugate
WO2016177771A1 (en) 2015-05-04 2016-11-10 Apogenix Ag Single-chain cd40-receptor agonist proteins
AR105616A1 (es) 2015-05-07 2017-10-25 Lilly Co Eli Proteínas de fusión
JP6983075B2 (ja) 2015-06-02 2021-12-17 ノヴォ ノルディスク アー/エス 極性の組換え延長部を有するインスリン
EP3356407B1 (en) * 2015-10-02 2021-11-03 F. Hoffmann-La Roche AG Bispecific anti-cd19xcd3 t cell activating antigen binding molecules
CN108699120B (zh) 2015-11-16 2022-05-13 Ubi蛋白公司 用于延长蛋白质半衰期的方法
CN110267674A (zh) 2016-07-08 2019-09-20 奥美药业有限公司 包含瘦素的融合蛋白及其生产和使用方法
RU2764197C1 (ru) 2016-09-23 2022-01-14 Ханми Фарм. Ко., Лтд. Аналоги инсулина с пониженной аффинностью к рецептору инсулина и их применение
WO2018073185A1 (en) 2016-10-17 2018-04-26 Vetoquinol Sa Modified antibody constant region
EP3939605A1 (en) 2016-12-09 2022-01-19 Akston Biosciences Corporation Insulin-fc fusions and methods of use
TW201835099A (zh) 2017-03-07 2018-10-01 美國凱斯西方瑞瑟夫大學 藉由第四雙硫鍵穩定之單鏈胰島素類似物
WO2018217976A1 (en) 2017-05-25 2018-11-29 Bristol-Myers Squibb Company Antagonistic cd40 monoclonal antibodies and uses thereof
BR112020002871A2 (pt) 2017-08-15 2020-07-28 Kindred Biosciences, Inc. variantes fc de igg para uso veterinário
EP3781147A4 (en) 2018-04-16 2022-04-20 University of Utah Research Foundation Glucose-responsive insulin
KR20210029210A (ko) 2018-06-29 2021-03-15 악스톤 바이오사이언시스 코퍼레이션 초장기 작용 인슐린-fc 융합 단백질 및 사용 방법
US11267862B2 (en) 2018-06-29 2022-03-08 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
CA3114395A1 (en) 2018-09-25 2020-04-02 Absci, Llc Protein purification methods
TW202028229A (zh) 2018-10-05 2020-08-01 丹麥商諾佛 儂迪克股份有限公司 包含胰島素肽及egf(a)肽之雙功能化合物
EP3883957A4 (en) 2018-11-19 2022-08-17 Case Western Reserve University SINGLE-CHAIN INSULIN ANALOGS WITH POLYALANINE C-DOMAIN SUBSEGMENTS
US20220235111A1 (en) 2019-05-17 2022-07-28 Case Western Reserve University Variant Single-Chain Insulin Analogues
WO2021011827A1 (en) 2019-07-16 2021-01-21 Akston Biosciences Corporation Ultra-long acting insulin-fc fusion proteins and methods of use
TWI844709B (zh) 2019-07-31 2024-06-11 美商美國禮來大藥廠 鬆弛素(relaxin)類似物及其使用方法
FI4073098T3 (fi) 2019-12-19 2023-11-15 Akston Biosciences Corp Ultrapitkävaikutteiset insuliini-Fc-fuusioproteiinit ja niiden käyttömenetelmät
US11186623B2 (en) 2019-12-24 2021-11-30 Akston Bioscience Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
US11192930B2 (en) 2020-04-10 2021-12-07 Askton Bioscences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
US11198719B2 (en) 2020-04-29 2021-12-14 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
CA3254188A1 (en) 2022-03-16 2025-03-04 Beijing Tuo Jie Biopharmaceutical Co. Ltd. Human insulin analogue, and fusion protein thereof and medical use thereof

Also Published As

Publication number Publication date
EP4073098A1 (en) 2022-10-19
DK4073098T3 (da) 2023-11-20
US12606605B2 (en) 2026-04-21
LT4073098T (lt) 2023-12-11
BR112022012071A2 (pt) 2022-08-30
JP7405486B2 (ja) 2023-12-26
HUE064376T2 (hu) 2024-03-28
ZA202206047B (en) 2023-08-30
KR102865175B1 (ko) 2025-09-30
US11555058B2 (en) 2023-01-17
AU2020407365B2 (en) 2023-09-21
CA3159486A1 (en) 2021-06-24
EP4282473A3 (en) 2024-02-21
US20210309709A1 (en) 2021-10-07
CN114846025A (zh) 2022-08-02
NZ788617A (en) 2024-10-25
FI4073098T3 (fi) 2023-11-15
HRP20231433T1 (hr) 2024-03-29
SI4073098T1 (sl) 2023-12-29
US20230250148A1 (en) 2023-08-10
US11352407B2 (en) 2022-06-07
AU2020407365A1 (en) 2022-06-09
CN114846025B (zh) 2025-11-11
KR20250142943A (ko) 2025-09-30
KR20220115975A (ko) 2022-08-19
EP4073098B1 (en) 2023-09-27
US20220064251A1 (en) 2022-03-03
IL294051A (en) 2022-08-01
JP2023507376A (ja) 2023-02-22
WO2021126584A1 (en) 2021-06-24
EP4282473A2 (en) 2023-11-29

Similar Documents

Publication Publication Date Title
DK3892628T3 (da) Ultra-langtidsvirkende insulin-fc-fusionsproteiner og fremgangsmåder til anvendelse
DK4232463T3 (da) Interleukin-2-fc-fusionsproteiner og fremgangsmåder til anvendelses
IL288373A (en) flt3l-fc fusion proteins and methods of use
DK4073098T5 (da) Ultralangtidsvirkende insulin-Fc-fusionsproteiner og fremgangsmåder til anvendelse
DK3565579T3 (da) Pd1-41bbl-fusionsprotein og fremgangsmåder til anvendelse deraf
IL281783A (en) Sirpα binding proteins and methods of use thereof
IL281683A (en) Dll3 binding proteins and methods of use
DK3565828T3 (da) Sirp1 alpha-41bbl-fusionsprotein og fremgangsmåder til anvendelse deraf
DK3618928T3 (da) Anti-Sortilin-antistoffer og fremgangsmåder til anvendelse deraf
DK3601358T5 (da) Anti-trem2-antistoffer og fremgangsmåder til anvendelse deraf
DK3618863T3 (da) Anti-tigit-antistoffer og fremgangsmåder til anvendelse deraf
DK3761980T3 (da) Aminosyreforbindelser og fremgangsmåder til anvendelse
IL280102A (en) Fusion protein containing PD1-4-1BBL and methods of using it
DK3660045T3 (da) Polypeptid, fremgangsmåde til fremstilling deraf og anvendelse deraf
DK3966207T3 (da) Phenylaminopyrimidinamid-autophagi-hæmmere og fremgangsmåder til anvendelse deraf
DK3694529T3 (da) Trispecifikke proteiner og anvendelsesfremgangsmåder
DK3966206T3 (da) Heteroarylaminopyrimidinamid-autophagihæmmere og fremgangsmåder til anvendelse deraf
DK3788044T3 (da) RIP1-hæmmende forbindelser og fremgangsmåder til fremstilling og anvendelse heraf
DK3774789T3 (da) BRM-målrettede forbindelser og tilhørende fremgangsmåder til anvendelse
IL275742A (en) IL-22 FC fusion proteins and methods of use
IL280103A (en) Fusion protein containing SIRPalpha-4-1BBL and methods of using it
DK3525583T3 (da) Anti-c1s-antistoffer og fremgangsmåder til anvendelse deraf
DK3743447T3 (da) B7-H4-antistoffer og fremgangsmåder til anvendelse deraf
DK3491025T3 (da) Fcrn-antistoffer og anvendelsesmetoder heraf
IL285401A (en) Anti-clec2d antibodies and methods of use thereof